pleasure you and Jake, to It’s good speak you, morning, with a Thank everyone. today.
by anyone to the who our offer to condolences I’d the into performance, of like get I details coronavirus. Before has been impacted my quarterly
to Teleflex have day. to put my health all as risks care to returned workers, sincere every workers including practice, the COVID-XX at themselves As who battle thanks who clinical well
they provide to products and to them last normal, have world. like as been Teleflex employees hospitals, inspire take and our continue around to months that recognize the few to we extraordinary patients in to our from a ways the These able employees need me also ensure moment most. to stepped who have up I’d the far are clinicians
big Teleflex you to thank So a employees. all
to on quarter our one Now results.
So, of global a for solid pandemic. of when the you year consideration Particularly Teleflex. to quarter into start the the take XXXX escalation was first the COVID-XX
one, quarter X%. growth During generated constant we currency of revenue
While on was our growth currency approximately a day selling neutral basis, X.X%. revenue constant
and generated Quarter to decline our driven X the But XX a by line our XX.X%, gross basis performance margin EMEA experienced respectively. translated at a This XXX points the Asia growth into was operating growth margins the COVID-XX. of due and Americas, and OEM adjusted of XX.X% of line. margin segment year-over-year operating perspective, basis we at points From and revenue gross margin segments.
a earnings we share increase as XX.X% share While achieved robust the of earnings totaled standpoint, from per adjusted per $X.XX during an year-over-year quarter.
few in navigating diversified drive have strength to It ability statement past throughout I’m years. very a the significant leverage extremely global pleased our of environment. operating built over through income a is to the we difficult portfolio the testament the while
saw Next, helpful our thought how regarding be quarter I first provide would we COVID-XX it context some to results. impact
mind it business we to our that a related keep And be impacting all be in XX, earnings provided It event. to to $X As China. was $X.XX within and guidance would was between is to from guidance only when only of assumed and previously per $XX financial we on X be reminder, largely revenue This XXXX February million COVID-XX provided the negatively by that year share. our in quarter important was expected a assumed COVID-XX China. our impacted million between $X.XX full adjusted and
largely the first a progress the first of much line in as China. our as impact and with see January negative did and not March, well of months were we of we February expectations, outside initial of the quarter, through X As weeks
spread further hospitals the in began to nonemergent considered any with procedures be of and postpone a the we virus and the nature, more announcement requiring the impact few of the as globally, that to However, during from coupled last to are College general, see quarter. of the or pronounced to negative surgeon weeks American elective began Surgeons
only still correlated is product And elective felt while our we an business. X/X portfolio we estimate impact procedures, nonemergent or that our to to of
weeks of primarily our within occurred few Americas. During largely the product headwind Interventional lines. the within [Indiscernible] additional and Interventional Surgical March, And last Urology, this Access
increased Americas sales see from products. within did some respiratory of certain We offset the
the enough revenue the not was that to canceled lost offset from However, procedures. and margins
to products, of and significant products Anesthesia due world Access, part results Vascular our We and increased a of demand saw increased we demand treatment patients certain the respiratory benefited our this EMEA. the Turning used that to COVID-XX. within for in estimate for with
While COVID-XX our with within impact line Asia, the assumptions. was from previous in
a revenue of original guidance was world. in that slightly as only, the adjusted the initial end impact in experienced expanded worse while our the we our than quarter, headwind at line, earnings China This China our to of is the despite with an contemplated the anticipating the during high the rest headwind virus total, estimates. was has beyond In line guidance
the forward thoughts the look like our year. provide to Next, I’d to remainder of as you we with
guiding decision-making principles foremost, for I manage the framework the and you crisis: as the we customer the with accelerate through a business established to through and communicate to first, safety First transparency, recovery. with employee want share and
me just of and On that our safety health let workers the safety is paramount. first, say
with health guidelines local As the implemented and have authorities. such, World organization, we Health health safety best accordance for practices and CDC the in
from engage benefit to a through management investing transparency, managing to formed with demand on due for crisis employees COVID-XX adequate with the certain updates. to regular accelerate maintaining to have support remain phased necessary And recovery, to coordinate and lines team our a increased business resources we global our the to communicating product we recovery. actions committed For the while inventory
minimal supply Second. our have To had date, we disruptions chain. global within
change fluid very can a things quickly. is and this situation However,
As capacity within facilities an Malaysia, impacted by respiratory, in because operating those certain this in restrictions of products countries. are our placed But of certain not we at currently both required fight at the and the not restriction India airway, of critical has governments example, COVID-XX. and vascular XXX%
have able weeks. Indeed, families, respiratory in significant past to achieve six critical production product been we to increases for over the four
expect up XXX% In restrictions within next in few to learned which government enable advance we was placed days our the previously, fact, they back production position to Malaysian facility removing this increase only a be Malaysian to earnings call, in we of week. a us capacity certain the that will had over our
our elevated of our customer demand meet associated to having times respiratory, most rates we increased delivery to on are products. Anesthesia continue certain for can we and best allocation while with do those and to order Vascular to due products products, And place
elective Third, portions based of on Interventional of and certain the nonemergent trends that product Access that deferral began and March, expect latter Interventional will to half in and our negatively we of our impact continue Surgical lines. procedures the certain business Urology
to deferred. mentioned within earlier, we estimate the not that about procedures procedures being are deferred some due that I to is being product say these capable As only of all criticality of of patients. used are our is X/X that That of portfolio
procedure patient’s as get condition cannot performed. occur are simply believe they wait improving not underlying because the indefinitely also deferment a We to
Phase of in in United Conversely, impacted begins from believe that to I states recovery COVID benefit and would of II. as could a our procedures White day by elements portfolio reopen, we recover outpatient But the case reach House portfolio States remainder once the Phase the elective status. our
Further, I’d like to that advise community exposure. our the very has portfolio equipment investment capital limited
had to procedures that a that remaining procedures will significant performed we on designated to of XX% postpone. office have they users The the amount their high-volume our have the require in procedures not belief of our It the perform is are in Phase an ASC setting. or Phase an belief is and would first to previously stay begin I. had are as are It recovery also performed with discussions come I. should they a that consumer belief also. hospital we is UroLift, back is once UroLift that the of confidence be Approximately overnight see that Based re-established, those do here XX% to several in capacity
Following would business our next. that envision Access rebound and procedures Interventional UroLift of would Surgical we return being performed, the
advantage As sure hand. making amount a result, that we increased includes be take when to have of and demand building it the inventory have of occurs. This to positioned on able our stock business safety that certain appropriate we
make laid-off and procedures our Rather, in employees. to key wanted our that them we clinical Additionally, personnel sales we returning. not of anticipation and motivated retain sure we keep furloughed have
adjustment the organization. we as the made the have mitigate We’ve the to of our reduction negative management of UroLift any national the and that expenses. financial somewhat executive to not of impact was This to stemming decision well curtail discretionary steps to includes delay the critical operating taken direct-to-consumer procedures, However, spending campaign. certain as elimination also compensation from certain
given said, remove that long-term remain to in timing well and future. accurately I we COVID Despite our our the to opportunity scope predict guidance. global the positioned significant, the our withdrawing storm our business guidance, we remains and XXXX previously provided cannot are is of that and recovery, confident the needing With financial weather XXXX accelerate that
will unless of which of let’s increase said, otherwise results. a revenues. the revenues delivered I X.X%. segment first will first rates represents $XXX an the quarter in of our on Americas I begin attention financial currency constant refer million to that a basis. are review to turn With And with growth noted, our reportable The quarter,
within for been was respiratory impact driven and day neutral would been Growth Interventional categories While higher, COVID-XX. the it a had significantly Access selling the on region Vascular Americas approximately have by negative this not product of grew X%. our basis, and Urology,
EMEA reported X.X% representing revenues quarter, of the in growth. first $XXX.X million
And largely strength our a I earlier, approximately EMEA we EMEA that on neutral also respiratory broad estimate benefited selling within basis, grew was ordering Access and driven COVID-XX. X%. stated by Vascular While this day from related elevated as portfolios. region to Growth across
the this that $XX.X currency no day decline growth, of we differences, totaled X.X%. There selling revenue first constant it of would COVID-XX. positive Revenues have had region’s rate to growth the was represents impact we in Asia. to Turning from which been a estimate quarter, for however, million not impact had
coupled had of of sales of selling business. a during impact OEM our first revenues the reported million differences on We believe increase products. not little Growth mixture a our quarter. our Like on the acquisition additional represents XX.X%. increase material OEM an of from an by Asia, existing was of business day had do quarter, $XX.X that lastly, in which COVID-XX of the revenue business coming OEM HPC, volumes And with driven impact first
However, year. move through the that may throughout we change as
under performing acquisition the HPC, is to I’m very the our with efforts and integration relates underway, leadership. the it how well As of are pleased business
discussion with now a category. my Let’s comments also global on be global regarding prior category will a our Consistent product currency revenues move commentary to by of constant on basis. growth product segments, our reportable
to within X.X% and Starting quarter with both growth to Vascular our Due increased Access. $XXX.X million. revenues EZ-IO X PICC products,
the COVID-XX during We selling one rates of positively estimate growth. first growth impacted negatively products quarter, our impacted while that vascular the day less
Moving to Access. Interventional
revenue million, First $XX.X X.X%. quarter was a represents decline of which
quarter, MANTA, During declines as intra-aortic less and day. by offset growth as OnControl one well catheters in in than selling the drainage and balloons complex more was
difficult catheter X, Interventional still reprocessing comparison during associated business QX our in a revenue divested quarter occurred faced Our with as also ‘XX. products
procedures that were Access products impacted first the the growth rates canceled. of our Additionally, nonemergent as Interventional COVID-XX quarter during we negatively certain estimate
was revenue a of impact Now and lower of decline million, was The masks X well X.X%. due as to to certain the of Anesthesia. revenue which Anesthesia less as laryngeal products, one sales Quarter $XX.X in decline day. represents selling regional
estimate we it during impact negligible a that COVID-XX, to relates it quarter. the had first As
declined the day. our less Surgical Atlanta plant by one $XX.X shutdown largely business. COVID-XX to driven to and and million, Shifting impact of Revenue a XX.X% Sterigenics by selling
of Quarter Urology. revenue were as million. during and X $XX.X the cancellation the weeks February, March, higher Interventional January XX.X% of of significantly we as increased rate start the a any year. procedures Revenue our growth to because the Unfortunately, as to first more COVID-XX other growth off to line elective Moving of than UroLift than well impacted of rates months the to product couple this was portfolio. quarterly achieved within fantastic
category, COVID-XX. as of be As will respiratory finally, and That first revenue resulting growth completes be UroLift In grew filters UroLift and for the $XX.X is million. I quarter totaling urology that in humidification, quarter from due and estimate procedures envision to other States products one on an of X.X% earlier, lower-acuity the such care part, during setting large United respiratory X products, of that our my increased reopens. the once would demand was performance. we comments procedure consists performed stated we to performed because the And our types outpatient which
I call results. a more the would now of first for our Tom quarter financial like detailed over to turn to review Tom?
